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Abstract 
Background: Acute kidney injury (AKI) is a frequent complication of transcatheter aortic valve 
implantation (TAVI) and has been linked to preexisting comorbidities, peri-procedural hypotension, 
and systemic inflammation. The extent of systemic inflammation after TAVI is not fully understood. 
Our aim was to characterize the inflammatory response after TAVI and evaluate its contribution to the 
mechanism of post-procedural AKI.
Methods: One hundred and five consecutive patients undergoing TAVI at our institution were includ-
ed. We analyzed the peri-procedural inflammatory and oxidative stress responses by measuring a range 
of biomarkers (including C-reactive protein [hsCRP], cytokine levels, and myeloperoxidase [MPO]), 
before TAVI and 6, 24, and 48 hours post-procedure. We correlated this with changes in renal function 
and patient and procedural characteristics. 
Results: We observed a significant increase in plasma levels of pro-inflammatory cytokines (hsCRP, 
interleukin 6, tumor necrosis factor alpha receptors) and markers of oxidative stress (MPO) after 
TAVI. The inflammatory response was significantly greater after transapical (TA) TAVI compared 
to transfemoral (TF). This was associated with a higher incidence of AKI in the TA cohort compared 
to TF (44% vs. 8%, respectively, p < 0.0001). The incidence of AKI was significantly lower when  
N-acetylcysteine (NAC) was given peri-procedurally (12% vs. 38%, p < 0.005). In multivariate analy-
sis, only the TA approach and no use of NAC before the procedure were independent predictors of AKI.
Conclusions: TAVI creates a significant post-procedural inflammatory response, more so with the TA 
approach. Mechanisms of AKI after TAVI are complex. Inflammatory response, hypoperfusion, and oxi-
dative stress may all play a part and are potential therapeutic targets to reduce/prevent AKI. (Cardiol J )
Key words: severe aortic stenosis, transcatheter aortic valve implantation, acute  




20XX, Vol. XX, No. X, XXX–XXX
DOI: 10.5603/CJ.a2020.0169 





Acute kidney injury (AKI) is a recognized 
complication of conventional valve surgery using 
cardiopulmonary bypass and is associated with poor 
outcomes [1]. Aside from preexisting comorbidi-
ties, important contributors include hypotension 
during cardiopulmonary bypass and post-operative 
systemic inflammation. TAVI does not require 
cardiopulmonary bypass, but post-procedural AKI 
frequently occurs, in 19% to 33% of patients [2, 3]. 
Although the prevalence of chronic kidney disease 
in transcatheter aortic valve implantation (TAVI) 
patients is higher than in surgical cohorts (because 
of their greater age and higher overall risk), the 
exact mechanism of AKI following TAVI is unclear. 
In some studies, AKI has been linked with the 
volume of intra-operative contrast agent used [4], 
but other factors have also been identified including 
blood transfusions [5]. 
Little is known about the magnitude of the 
inflammatory response, oxidative stress, and 
myocardial/renal injury after TAVI. Systemic 
inflammatory response syndrome (SIRS) after 
TAVI, measured using C-reactive protein (CRP) 
and body temperature, is an independent predic-
tor of mortality [6]. The precise etiology of SIRS 
in this setting is unclear but may in part relate to 
myocardial damage and pump failure. It is clear 
that myocardial damage is a poor prognostica-
tor, and Yong et al. [7] have shown recently that 
a peri-procedural increase in markers of myocardial 
injury independently predicts a poor outcome at 
30 days after TAVI. Inflammatory markers such as 
interleukin 6 (IL-6) [8] and tumor necrosis factor 
alpha (TNFa) [9] have been correlated with AKI 
after coronary artery bypass grafting, and although 
likely to be relevant, they have not previously been 
demonstrated in a TAVI population.
The aim of our study was to analyze and clarify 
the systemic inflammatory response, the change 
in oxidative stress, and magnitude of myocardial 
injury after TAVI and thereafter to explore associa-
tions with AKI and procedural outcome. 
Methods
Patient population 
We prospectively included 105 consecutive 
patients with severe aortic stenosis, who under-
went TAVI either via a transfemoral (TF TAVI, 
n = 60) or a transapical approach (TA TAVI, n = 45) 
using Edwards-Sapien and Sapien XT transcatheter 
heart valves (Edwards Lifesciences, Inc., CA, USA) 
between July 2009 and July 2012. The study was 
approved by the local research Ethics Committee. 
All subjects provided written informed consent.
Mortality tracking was undertaken by the 
National Health Service Central Register using 
unique patient identifiers for all patients enrolled 
in this study.
The primary endpoint of the study was the 
occurrence of AKI. We utilized the Acute Kidney 
Injury Network classification of AKI [10]. Clinical 
outcome and complications were recorded using 
Valve Academic Research Consortium-2 definitions 
[11]. The estimated glomerular filtration rate was 
calculated by the simplified Modification of Diet in 
Renal Disease formula.
Systemic inflammatory response syndrome 
was defined as fulfilling at least two of the following 
criteria during the first 48 h after TAVI: tempera-
ture < 36.0oC or > 38.0oC, heart rate > 90 bpm, 
and leucocyte count > 12 or < 4 (109/L).
Preoperative protocol to prevent AKI 
N-acetylcysteine (NAC) was given at the 
physician’s discretion 1 day pre-TAVI at 600 mg 
bd and continued for 48 h post TAVI in 53% of 
patients (n = 60). 
TAVI procedure and anesthesia
Transfemoral TAVI was performed using the 
conventional technique [12]. A similar general 
anesthetic technique was used in all cases regard-
less of access site. Surgical exposure of the femoral 
artery was used as the mode of arterial access in TF 
patients. Initial fluid replacement was with 1000 mL 
compound sodium lactate. Blood pressure was main-
tained (systolic > 100 mmHg) during the procedure 
with metaraminol boluses (50–100 mg). No patient 
required catecholamine infusion post-procedure.
Invasive cardiac output monitoring
The FloTrac system uses a clinically validated 
algorithm to provide continuous cardiac output, 
stroke volume, and systemic vascular resistance 
measurements. Heart rate, and systolic and dias-
tolic blood pressure were recorded at each time 
point. A Vigileo™ (Edwards Lifesciences, Irvine, 
CA, USA) monitor with software version 1.01 
was connected to the radial artery catheter via 
a FloTrac™ (Edwards Lifesciences, Irvine, CA, 
USA) pressure sensor. 
Biomarkers
Blood samples were obtained pre-TAVI and 
4–6 h, 22–26 h, and 44–52 h post-procedure from 
2 www.cardiologyjournal.org
Cardiology Journal 20XX, Vol. XX, No. X
a central line. Intervals for sampling were based on 
data from Sinning et al. [13], in which an elevated 
leucocyte count and IL-6 was already observed 
4 h after TAVI and reached a peak level at 48 h after 
TAVI. Serum was isolated within 1 h of collection 
and samples stored at –80°C until thawed for de-
termination of biomarkers, which were measured 
as follows:
Markers of inflammation and oxida-
tive stress. Serum hsCRP was measured using 
a latex-enhanced immunoturbidimetric assay (PZ 
Corman, Lublin, Poland). The precision of the as-
says is expressed as the between-run coefficient 
of variation (%CV). The %CV of the hsCRP assay 
for concentrations of 0.047, 0.218, and 0.976 mg/L 
was 6.97, 3.34, and 1.23%, respectively.
Tumor necrosis factor alpha, tumor necrosis 
factor alpha receptor 1 (TNFaR1), tumor necrosis 
factor alpha receptor 2 (TNFaR2), and IL-6 were 
measured using a Luminex® Bead-based Multiplex 
Assay system. 
Serum myeloperoxidase (MPO) was measured 
using the quantitative sandwich enzyme-linked 
immunoassay (ELISA) technique (R&D Systems 
Europe Ltd., United Kingdom). The %CV of the 
MPO assay for concentrations of 15.7, 32.4, and 
64.1 ng/mL was 7.5%, 7.7%, and 6.6%, respectively.
Markers of renal injury. Plasma neutrophil 
gelatinase-associated lipocalin (NGAL) was meas-
ured using a sandwich ELISA with wells coated 
with a monoclonal antibody against NGAL (BioPorto 
Diagnostics A/S, Denmark). The %CV of the NGAL 
assay for concentrations 1.2–4 pg/mL was 3%. 
The assay is linear up to 1000 pg/mL.
Serum cystatin C was measured using a latex-
-enhanced immunoturbidimetric assay (Siemens 
Healthcare Diagnostics Ltd., UK). The lowest 
concentration that can be distinguished from zero 
is 0.1 mg/L.
Markers of myocardial injury. Serum cre-
atine kinase MB (CK-MB) was measured using 
the Immulite 2000 assay (a chemiluminescent 
enzyme-labeled immunometric assay, reagent 
from Siemens Healthcare Diagnostics, Ltd., UK). 
The %CV of the CK-MB assay for concentrations 
of 13.9, 54.3, and 95.4 ng/mL was 5.8%, 5.5%, and 
6.1%, respectively.
Markers of heart failure and neurohormo-
nal activation. N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) was measured on a Siemens 
Immulite 2000 analyzer (a two-site chemilumines-
cence immunoassay). The %CV of the BNP assay 
for concentrations of 35.6, 1430, and 29,725 pg/mL 
was 5.4%, 3%, and 4.1%, respectively.
Receptor for interleukin-33 (ST2) (R&D Sys-
tems Europe, Ltd., UK) was measured with a quan-
titative sandwich enzyme immunoassay technique. 
The %CV of the ST2 assay for concentrations of 
273, 628, and 1027 pg/mL was 5.6%, 4.4%, and 
4.5%, respectively.
Aldosterone (Siemens Medical Solutions Diag-
nostics, 5700 West 96th Street, LA, CA 90045-5597, 
USA) was measured with a solid-phase radioim-
munoassay, based on aldosterone-specific antibody 
immobilized to the wall of a polypropylene tube. 
The %CV of the aldosterone assay for concentra-
tions of 65, 448, and 813 pg/mL was 3.5%, 15.3%, 
and 19%, respectively.
Statistical analysis 
Data are presented as mean ± standard de-
viation and ± SEM when appropriate. Categorical 
variables are given as frequencies and percentages. 
The Fisher exact test was used to compare cat-
egorical variables in different groups. Continuous 
variables were tested for normality with the Sha-
piro-Wilk test. For continuous variables, Student’s 
t-test or Kruskal-Wallis test, as appropriate, was 
performed for comparison between two groups. 
Two-way repeat measures ANOVA followed by 
Tukey post hoc test was used to compare groups 
at multiple time points. Variables with evidence 
of heterogeneity of variance were analyzed with 
nonparametric tests.
Logistic regression modeling was used to 
assess the short-term outcome and to determine 
independent predictors of AKI. In a multivariate 
regression analysis, we adjusted for significant 
predictors of 12-month mortality in the univariate 
analysis. Survival curves according to the occur-
rence of AKI were plotted by the Kaplan-Meier 
method and compared using the Wilcoxon test. 
We employed a univariate Cox proportional hazard 
model to examine the association of AKI and other 
clinical characteristics with cumulative 12-month 
mortality and to evaluate the impact on long-term 
clinical outcome. P < 0.05 was considered to be 
statistically significant. 
Analyses were performed using the JMP 9 
statistical package (SAS, USA).
Results
Pre-procedural patient characteristics
Baseline patient characteristics and use of 
pre-procedural medications with potential effect on 
post-operative kidney function are summarized in 
Table 1. AKI was associated with peripheral vascu-
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lar disease, higher pre-procedural creatinine, lower 
transvalvular gradients, and higher N-GAL levels. 
Only 29% of patients subsequently developing AKI 
had received NAC compared to 65% of those who 
did not develop AKI (p < 0.005). Forty-seven per 
cent (n = 21) of patients undergoing TA TAVI and 
65% (n = 39) undergoing TF TAVI received NAC. 
There was a higher rate (RR 5.7; 1.6–25.1, p < 0.05) 
of AKI in patients who did not receive NAC (38% 
vs. 12%, p < 0.005). This difference was significant 
in the TF group (19% vs. 3%, p < 0.05) but not in 
the TA group (54% vs. 29%, p = 0.08).
Procedural outcome and predictors  
of post-TAVI AKI
The valve prosthesis was successfully de-
ployed in all patients (100%) with no peri-procedur-
al deaths (0%) and no conversion to open surgery 
(0%). The combined early safety endpoint at 30 
days was 31% (n = 33). 










Age [years] 84 ± 6 84 ± 6 83 ± 5 0.8
Male gender 50 (48%) 38 (47%) 12 (50%) 0.8
logistic EuroSCORE [%] 23 ± 11 22 ± 10 26 ± 12 0.2
Coronary artery disease 51 (49%) 39 (48%) 12 (50%) 0.5
Peripheral vascular disease 18 (17%) 9 (11%) 9 (38%) < 0.005
Previous MI 13 (12%) 8 (10%) 5 (20%) 0.2
Previous cardiac surgery 22 (21%) 15 (19%) 7 (29%) 0.3
Previous PCI 19 (18%) 12 (15%) 7 (29%) 0.1
Previous stroke/TIA 15 (15%) 9 (11%) 6 (25%) 0.1
Chronic obstructive pulmonary disease 32 (31%) 27 (33%) 5 (21%) 0.23
Pulmonary hypertension (> 60 mmHg) 16 (15%) 11 (13%) 5 (21%) 0.7
Diabetes 25 (24%) 17 (21%) 8 (33%) 0.2
Baseline hemoglobin [g/dL] 12.4 ± 1.6 12.5 ± 0.2 11.8 ± 0.3 0.2
Creatinine [mmol/L] 94 ± 28 91 ± 3 105 ± 6 < 0.05
eGFR [mL/min/1.73 m2] 61 ± 16 63 ± 2 56 ± 3 0.05
LVEF [%] 53 ± 12 53 ± 1 53 ± 3 0.93
AVA [cm2] 0.68 ± 0.18 0.69 ± 0.02 0.69 ± 0.02 0.8
Peak pressure gradient [mmHg] 80 ± 25 83 ± 3 77 ± 5 0.3
Mean pressure gradient [mmHg] 46 ± 16 48 ± 2 42 ± 3 0.1
Left ventricle mass [g] 171 ± 51 171 ± 6 167 ± 11 0.5
Cystatin C [mg/L] 1.09 ± 0.51 1.04 ± 0.33 1.13 ± 0.37 0.3
NT-proBNP [pg/mL] 4618 ± 5934 4513 ± 752 4962 ± 908 0.8
NGAL [μg/L] 116.4 ± 65.0 108.8 ± 6.5 141.3 ± 18.4 < 0.05
Pre-procedural medications
Pre-procedural NAC 60 (57%) 53 (65%) 7 (29%) < 0.005
Thiazides 9 (9%) 5 (6%) 4 (17%) 0.2
NSAIDs 60 (58%) 46 (58%) 14 (58%) 1.0
Loop diuretics 61 (59%) 47 (59%) 14 (58%) 1.0
ACEI/ARB 45 (44%) 34 (43%) 11 (46%) 0.8
MI — myocardial infarction; PCI — percutaneous coronary intervention; TIA — transient ischemic attack; eGFR — estimated glomerular filtra-
tion rate; LVEF — left ventricular ejection fraction; AVA — aortic valve area; NT-proBNP — N-terminal pro-B-type natriuretic peptide; NGAL — 
neutrophil gelatinase-associated lipocalin; NAC — N-acetylcysteine; NSAIDs — non-steroidal anti-inflammatory drugs; ACEI — angiotensin 
converting enzyme inhibitors; ARB — angiotensin II receptor blockers
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Acute kidney injury occurred more often in TA 
patients (44%, n = 20, TF: 8%, n = 5; p < 0.0001) 
(Fig. 1A). There was no significant difference in 
baseline creatinine between the TF and TA groups 
(99 ± 4 vs. 90 ± 4 umol/L, NS), and there was no 
difference in baseline estimated glomerular filtration 
rate (62 ± 2 vs. 59 ± 2 mL/min, NS), hemoglobin 
(12.4 ± 0.2 vs. 12.2 ± 0.2 g/dL, NS), or volume of 
contrast used during the procedure (109 ± 9 vs. 
126 ± 5 mL, NS, TA vs. TF, respectively). There 
was a significant difference in total rapid pacing time, 
with longer rapid pacing in the TA group (TF 44 ± 
± 3 vs. TA 75 ± 8 s, p < 0.0005).
Procedural characteristics and post-procedural 
complications are summarized in Table 2. 
In multivariate analysis TA TAVI and absence 
of NAC use pre-procedure were independent pre-
dictors of AKI (Table 3).
There was no difference in 30-day mortality 








































Figure 1. A. Incidence of acute kidney injury (AKI) according to access site (transfemoral [TF] vs. transapical [TA]). 
There was a significantly higher frequency of AKI in the transapical group (chi-square test, p < 0.005); B. Kaplan-Meier 
curves for patient with AKI and with no post-procedural AKI (Wilcoxon test, p < 0.05). There was higher mortality in 
the group developing AKI; *p < 0.005.
Table 2. Procedural characteristics and post-procedural complications (as defined by the Valve  









Route transapical 45 (43%) 26 (35%) 19 (79%) < 0.001
Valve size 23/26/29 mm 55/41/9 47/28/6 8/13/3 0.1
Volume of contrast [mL] 119 ± 52 117 ± 5 125 ± 13 0.6
Blood transfusion required 39 (37%) 28 (35%) 11 (46%) 0.3
Pacing time [s] 57 ± 37 54 ± 4 64 ± 10 0.4
Post-procedural complications
Myocardial infarction 0 (0%) 0 (0%) 0 (0%) NS
Stroke 1 (1%) 1 (1.2%) 0 (0%) 1.0
Major/life-threatening bleeding 20 (19%) 16 (20%) 4 (17%) 1.0
Major vascular/apical complications 2 (2%) 1 (1.2%) 1 (4.2%) 0.4
New conduction abnormality 4 (3.8%) 2 (2.5%) 2 (8.3%) 0.2
30-days mortality 8 (7.6%) 5 (6.2%) 3 (12.%) 0.4
Post-procedure aortic regurgitation (≥ moderate) 2 (2%) 0 (0%) 2 (8.7%) < 0.05
Device success 102 (96%) 81 (100%) 21 (87%) < 0.05
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without (12.5% vs. 6.2%, respectively, p = 0.4), 
but there was a significant difference in overall 
mortality (Fig. 1B). 
Characterization of inflammatory response
Inflammation and oxidative stress. TAVI 
was associated with a rise in pro-inflammatory cy-
tokines including hsCRP, and TNFa and its recep-
tors (R1 and R2). The magnitude of inflammation 
was associated with the severity of postprocedural 
AKI, especially at 44–52 h after the procedure 
(Fig. 2A, B). The inflammatory response was 
significantly greater after TA than after TF TAVI 
(Fig. 3A, D, E, F). 
Myeloperoxidase levels rose significantly af-
ter TAVI from 540 ng/L at baseline to 992 ng/L at 
4–6 h, to 1222 ng/L at 22–26 h, and to 1412 ng/L 
at 44–52 h (MANOVA, p < 0.0001), suggesting an 
increase in oxidative stress. Again, these chang-
es were more significant in stages II/III of AKI 
(Fig. 2B) and after TA TAVI (Fig. 3B). 
Interleukin 6 increased significantly after 
TAVI but to a greater extent in the AKI group 
(Fig. 4B). 
Systemic inflammatory response syndrome 
was observed in 8 (8%) patients in the TA group 
(TA 8% vs. TF 0%, p < 0.0005), and of these, 50% 
had AKI (NS).
Markers of renal injury. Baseline NGAL 
was significantly higher in the AKI group (Table 1). 
NGAL levels increased post-procedure in all pa-
tients (baseline 115 ± 7 pg/mL vs. 24 h 194 ± 
± 11 pg/mL, p < 0.0001), with a greater increase 
in patients who developed AKI (mean difference, 
respectively: 67 vs. 11,711 pg/mL, p < 0.005, 
Fig. 4A). 
Cystatin C levels rose significantly and were 
significantly higher at 44–52 h after TAVI in the 
group developing AKI (1.18 ± 0.5 vs. 1.71 ± 0.15, 
p < 0.005).
Markers of myocardial injury. There was no 
significant difference in myocardial injury between 
patients with and without AKI (CK-MB: 20 ± 1.7 
vs. 23 ± 14, respectively, NS). 
Markers of heart failure and neurohormo-
nal activation. We observed a significant increase 
in ST2 and NT-proBNP after TAVI but with greater 
Table 3. Multivariate logistic regression analysis 
for predictors of acute kidney injury after  
transcatheter aortic valve implantation.
Variables OR 95% CI P
NGAL 0.99 0.98–1.01 0.24




TA TAVI 7.0 2.0–29.9 0.002
No NAC pre-procedure 4.7 1.4–18.3 0.01
CI — confidence interval; NAC — N-acetylcysteine; NGAL — neu-
trophil gelatinase-associated lipocalin; OR — odds ratio; TA TAVI — 
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TNFa, TNFaR1, TNFaR2, MPO and CRP levels





















Figure 2. Levels of inflammatory markers and oxidative stress after transcatheter aortic valve implantation (TAVI) by 
stage of acute kidney injury (AKI); A. 22–26 h after TAVI; B. 44–52 h after TAVI. One-way ANOVA, followed by Tukey 
post-hoc test performed if ANOVA was significant, *p < 0.05 from post hoc test significant difference against group 
with no postprocedural AKI. The magnitude of inflammatory reaction measured by levels of tumor necrosis factor 
alpha (TNFa) and its receptors, myeloperoxidase (MPO) and C-reactive protein (CRP) 22–26 h after TAVI was higher in 
all patients who developed AKI regardless of its severity. On the other hand, 44–52 h after TAVI inflammatory markers 
remained high, but only in patients who developed AKI stage 2/3. 
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changes in the AKI group (Fig. 4C, D). There was no 
difference in aldosterone levels in the AKI group (not 
shown), but aldosterone was significantly higher after 
TA TAVI compared to TF TAVI (Fig. 3C).
Hemodynamic changes. No significant dif-
ference was observed in the first 24 h in heart 
rate, cardiac output, systolic blood pressure, di-
astolic blood pressure, and mean blood pressure 
in either group. Systemic vascular resistance was 
significantly lower at baseline and remained lower 
in patients who developed AKI (Fig. 5).
Discussion
This is the first study to characterize the 








































































































Figure 3. Changes in inflammatory markers and oxidative stress after transfemoral (TF) and transapical (TA) group 
4–6 h, 22–26 h, and 44–52 h post-procedure. A. High-sensitivity C-reactive protein (hsCRP); B. Myeloperoxidase 
(MPO); C. Aldosterone; D. Tumor necrosis factor alpha (TNFa); E. TNFaR1; F. TNFaR2. Two-way ANOVA followed by 
Bonferroni post hoc test, *p < 0.05. Levels of hsCRP, MPO, aldosterone, and TNFaR1 and TNFaR2 were significantly 
higher after TA transcatheter aortic valve implantation.
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explore its relationship with post-procedural AKI. 
We have identified pre- and peri-operative risk 
factors for developing AKI, including peripheral 
vascular disease, TA approach, and post-TAVI para-
valvular aortic regurgitation. Furthermore, there 
is an association between the risk of AKI and the 
magnitude of the inflammatory response.
On multivariate analysis, pre-TAVI renal im-
pairment was not associated with post-procedural 
AKI. Although not powered to show this definitive-
ly, our results are in concordance with previously 
published data [14] from a cohort of 642 patients, 
divided according to pre-procedural renal function, 
in which, similarly, pre-procedural renal function 
was not a predictor of post-procedural AKI. This 
suggests that factors other than pre-existing renal 
function contribute to the development of AKI [15].
The association between inflammatory re-
sponse and AKI after TAVI has been reported 
in another small study [16], with suggestion of 
less inflammation with the TF compared with 
the TA approach [17]. We too observed a greater 
increase in inflammatory markers and oxidative 
stress after TA compared with TF TAVI, and 
that TA TAVI was associated with a significantly 
greater rate of AKI. Consistent with this, we 
report a significant increase in pro-inflammatory 
cytokines (including IL-6 and TNFa receptors), 
which are involved in the acute phase of the in-
flammatory response. These pro-inflammatory 
cytokines activate hepatic synthesis of acute-
phase proteins including CRP, which were also 
significantly increased in our study. This inflam-
matory reaction has been noted to correlate with 
AKI and multi-organ failure in other medical 
settings [8]. Furthermore, the inflammatory re-
sponse provokes an increase in oxidative stress, 
which is a known cause of AKI. 
Figure 4. Changes in neurohormonal activation in acute kidney injury (AKI) and no AKI group 4–6 h, 22–26 h, and 
44–52 h post-procedure. A. Neutrophil gelatinase-associated lipocalin (NGAL); B. Interleukin 6; C. N-terminal pro-B- 
-type natriuretic peptide (NT-proBNP), D. Receptor for interleukin 33 (ST2); Two-way ANOVA followed by Bonferroni 
post hoc test, *p < 0.05. NGAL levels were higher pre-transcatheter aortic valve implantation (TAVI) and were rising 
after the procedure significantly more in the AKI group. Interleukin 6 levels increase after TAVI from 4–6 h continuing 
rise over next hours. The rise in interleukin 6 levels was significantly higher in the AKI group at 22–26 h and 44–52 h. 








































































































































































Figure 5. Changes in basic hemodynamics in acute kidney injury (AKI) and no AKI group 4–6 h and 22–26 h post-pro-
cedure; A. Heart rate (HR); B. Cardiac output (CO); C. Systemic vascular resistance (SVR); D. Systolic blood pressure 
(SBP); E. Diastolic blood pressure (DBP); F. Mean blood pressure (MBP). No significant difference was observed in 
the first 24 h in HR, CO, SBP, DBP, and MBP in either group. The SVR was significantly lower at baseline and remained 
lower in patients who developed AKI.
Sinning et al. [13] demonstrated that 46% of 
patients with SIRS develop AKI after TF TAVI, and 
we similarly found that 50% of patients with SIRS 
developed AKI. However, SIRS accounted only for 
17% of all patients who developed AKI, confirm-
ing that lesser inflammatory responses and other 
factors are clearly important.
Neutrophil gelatinase-associated lipocalin, 
often labelled a “renal troponin”, is a powerful 
predictor of AKI after onset of cell stressors such as 
ischemia-reperfusion or inflammation [18]. In the 
Translational Research Investigating Biomarker 
Endpoints in AKI study (TRIBE-AKI) elevated 
NGAL plasma levels predicted AKI and improved 
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risk stratification [1]. In our cohort, NGAL levels 
were significantly increased after TAVI, and levels 
were greater in the TA group. This suggests that 
significant renal ischemia-reperfusion injury is 
probably implicated in the development of AKI. We 
were not able to predict AKI based on measure-
ments of NGAL levels 4–6 h post-TAVI. Interest-
ingly, levels of NGAL were higher at baseline in 
patients who went on to develop AKI, suggesting 
a possible predictive value in this setting. 
Hemodynamic disturbance may also play 
a part in renal injury during TAVI. Procedural char-
acteristics such as temporary hypotension during 
rapid pacing or balloon predilatation, or rhythm dis-
turbances due to aberrant conduction or inotropic 
support, may be relevant. We, however, found 
no significant differences in major hemodynamic 
parameters between the group that developed 
AKI and those who did not, with no difference in 
duration of pacing nor size of valve prosthesis. 
Frequency of rapid pacing, type of prosthesis, and 
number of attempts to deploy a prosthesis were 
not examined but may be of interest. We have 
previously shown that left ventricular (LV) systolic 
function is transiently impaired post-TAVI, and 
this phenomenon may well be greater after a TA 
procedure [12]. Certainly, a longer rapid pacing 
time in the TA group (utilized by our surgeons 
for apical closure) can lead to myocardial stunning 
and transient depression of LV function [12]. More 
prolonged peri-procedural hypotension with subse-
quent myocardial damage in addition to myocardial 
injury related to direct apical access may both serve 
to activate the inflammatory response, which may 
explain excess AKI in the TA group. 
Using CK-MB, we found no significant differ-
ence in myocardial injury between patients with and 
without AKI. The findings may have been different 
using troponin, a more specific biomarker for myo-
cardial damage. Koskinas et al. [19] demonstrated 
the impact of post-procedural cardiac troponin 
elevation on both 30-day and 2-year prognosis. 
Mechanisms of troponin release during TAVI are, 
however, multifactorial, and as well as myocardial 
injury, they may reflect the complexity of underly-
ing coronary artery disease, concentric LV hyper-
trophy, peri-procedural particle embolization into 
the coronary circulation, and pre-existing renal 
dysfunction. Peripheral vascular disease was more 
common in the AKI group. A useful extension to the 
current study would be to include measurements of 
embolization such as carotid flow and transcranial 
Doppler to determine the contribution of peripheral 
embolization in the development of AKI.
B-type natriuretic peptide (BNP) has been 
shown to be a good predictor of AKI after other 
forms of cardiac surgery [20] and a general pre-
dictor of outcome in patients with AKI [21]. Con-
sistent with previously published data [22] we 
noticed a significant increase in BNP after TAVI with 
a greater BNP rise in patients developing AKI. 
Elevations of BNP may primarily reflect AKI in-
stead of LV dysfunction in this setting. Increased 
intravascular volume stimulating cardiac secretion 
and reduced renal clearance of peptides serving as 
key mechanisms [23–25]. ST2, a member of the 
interleukin-1 receptor superfamily, was identified 
as a potential novel biomarker in patients with acute 
heart failure [26]. ST2 is up-regulated in isolated 
cardiomyocytes exposed to mechanical strain, and 
its levels correlate well with acute LV dysfunction 
independently of BNP [27, 28]. We have previously 
shown that there is a significant increase in ST2 
levels after successful TAVI, perhaps in response to 
peri-procedural myocardial dysfunction [12]. In the 
current study we observed a significant increase in 
ST2 levels in the AKI group, and after TA TAVI more 
than after TF TAVI. Like BNP, ST2 (by blocking the 
effects of interleukin-33) has been linked with AKI 
in other settings [29]. 
Another important contributor to post-proce-
dural renal ischemia is moderate-severe post-TAVI 
paravalvular aortic regurgitation, which has previ-
ously been linked with AKI and severity associated 
with higher levels of BNP and troponin [6]. It is 
now widely accepted that para-prosthetic aortic re-
gurgitation is associated with increased in-hospital 
and mid-term mortality following TAVI [30–32]. 
It has been suggested that post-procedural 
AKI is related to the amount of radio-opaque 
contrast used during the procedure [4, 14]. This 
hypothesis was not supported by Kong et al. [16], 
nor by our data. We did not see any link between 
volume of contrast used during TAVI and AKI, 
although all contrast volumes used were low. The 
volume of contrast was slightly higher in the TF 
TAVI group, which had a lower risk of AKI. 
Tepel et al. [33] reported that NAC may pre-
vent acute renal dysfunction by antioxidant action. 
NAC acts indirectly by boosting endogenous lev-
els of the major cellular antioxidant, glutathione 
[34, 35]. Despite proven efficacy in experimental 
models [36], the use of NAC in preventing AKI 
after cardiac surgery and coronary angiography in 
clinical practice remains controversial [37]. There 
are no data about the effects of NAC on AKI after 
TAVI. We incidentally observed that patients not 
given NAC pre TAVI had a higher incidence of 
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post-procedural AKI, independent of access site 
and volume of contrast used. This may be influ-
enced by unmeasured confounding factors in-
cluding the appropriate clinical use in patients 
perceived to be at higher risk of AKI. 
Collectively, these data suggest that the mech-
anism of AKI is multifactorial and interdependent 
and seems to involve factors beyond hemodynamic 
disturbances including the systemic inflamma-
tory response, free radical-induced damage, and 
ischemia-reperfusion injury. 
Limitations of the study
Our study contains only a relatively small 
number of patients; therefore, certain associations 
may have been missed, and although the outcome 
of AKI was examined, the study was not powered to 
examine differences in temporal trend in develop-
ment of AKI. Though inflammatory marker elevation 
parallels AKI development, etiological considera-
tions are made with caution, and further studies are 
required to delineate underlying mechanisms. The 
association between AKI and NAC use is incidental 
and was not a randomized intervention in the study, 
so again it must be interpreted with caution.
Conclusions
Acute kidney injury after TAVI is predicted 
by the TA approach and absence of NAC therapy 
pre-procedure. TAVI generates a significant in-
flammatory response, with an associated increase 
in oxidative stress. There is also significant renal 
ischemia/reperfusion injury.
The changes in these processes are signifi-
cantly higher after TA TAVI, which may in part 
explain the higher incidence of AKI in this patient 
cohort. 
Our results inform case selection in this high-
-risk patient group and emphasize the importance 
of minimizing tissue damage and hemodynamic 
instability during the TAVI procedure, thus sup-
porting the technological drive towards a minimally 
invasive, fully percutaneous procedure. The use of 
NAC to protect the kidneys merits further study.
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